Alpha 2.0
Login Register
» Articles » PMID: 12135056

Beneficial Effect of Bezafibrate on Primary Sclerosing Cholangitis (three Case Reports)

Overview
Journal Am J Gastroenterol
Specialty Gastroenterology
Date 2002 Jul 24
PMID 12135056
Citations 5
Authors
Ryuichi Kita
Yuri Kita-Sasai
Ikuko Hanaoka
Toru Kimura
Hiroyuki Kokuryu
Seigo Takamatsu
Yukio Osaki
Naomi Tomono
Tsutomu Hachiya
Tatsuo Shimizu
Affiliations
Soon will be listed here.
Citing Articles

Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial.

Hatami B, Mosala M, Hassani A, Ehsani Ardakani M, Gholami S, Zali M Pharmacol Res Perspect. 2022; 10(4):e00984.

PMID: 35822553 PMC: 9277608. DOI: 10.1002/prp2.984.

Statins, Fibrates, and Other Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Cholestatic Liver Diseases.

Dubrovsky A, Bowlus C Gastroenterol Hepatol (N Y). 2021; 16(1):31-38.

PMID: 33867886 PMC: 8040906.

Treatment of autoimmune liver disease: current and future therapeutic options.

Trivedi P, Hirschfield G Ther Adv Chronic Dis. 2013; 4(3):119-41.

PMID: 23634279 PMC: 3629750. DOI: 10.1177/2040622313478646.

Endoscopy in the management of primary sclerosing cholangitis.

McLoughlin M, Enns R Curr Gastroenterol Rep. 2008; 10(2):177-85.

PMID: 18462605 DOI: 10.1007/s11894-008-0040-9.

The medical management of primary sclerosing cholangitis.

Michaels A, Levy C Medscape J Med. 2008; 10(3):61.

PMID: 18449341 PMC: 2329756.